Hangzhou Polymed Biopharmaceuticals Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety via a linker reported to be useful for the treatment of cancer.

Jing Medicine Technology (Shanghai) Ltd. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression.

Cytokinetics Inc. has disclosed fast type myosin-binding protein C (MYBPC2) inhibitors reported to be useful for the treatment of neuromuscular disorders.

Humanwell Pharmaceutical US Inc. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.

Hanmi Holdings Co. Ltd. has divulged heterocyclic derivatives acting as inhibitors of eukaryotic translation initiation factor 2-α kinase 4 (GCN2), eukaryotic translation initiation factor 2-α kinase 1 (HRI), eukaryotic translation initiation factor 2-α kinase 3 (PERK) and interferon-induced, double-stranded RNA-activated protein kinase (PKR; EIF2AK2) reported to be useful for the treatment of cancer, Alzheimer’s disease and immunological disorders.

Gilead Sciences Inc. has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Duality Biologics (Suzhou) Co. Ltd. has synthesized trabectedin derivatives reported to be useful for the treatment of cancer.

Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed glutaminyl-peptide cyclotransferase (QPCT; QC) and glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors reported to be useful for the treatment of cancer, fibrosis, atherosclerosis and more.

Aglaeapharma Inc. has described compounds acting as α2-adrenoceptor agonists reported to be useful for the treatment of rhinitis, pain, insomnia, inflammatory disorders, glaucoma, cancer, anesthesia and acute kidney injury, among others.

Anima Biotech Inc. has divulged collagen 1 (COL1) translation inhibitors reported to be useful for the treatment of cirrhosis, fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), alcoholic fatty liver and autoimmune diseases.